Source comparison
Mechanism of Action: Receptor Agonism vs Direct Hormone Replacement
Sermorelin acetate is a 29-amino-acid peptide analog of GHRH—the natural hormone secreted by the arcuate nucleus of the hypothalamus. When administered subcutaneously, sermorelin binds to GHRH receptors (GHRHR) on the cell membranes of somatotroph cells in the
This comparison does not assign a generated winner or score.
- Sermorelin acetate is a 29-amino-acid peptide analog of GHRH—the natural hormone secreted by the arcuate nucleus of the hypothalamus. When administered subcutaneously, sermorelin binds to GHRH receptors (GHRHR) on the cell membranes of somatotroph cells in the anterior pituitary gland. This binding activates Gs protein-coupled receptor signaling, which increases intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors like CREB (cAMP response element-binding protein). CREB then upregulates transcription of the GH1 gene, leading to increased synthesis and secretion of endogenous growth hormone into the bloodstream.
- The key mechanistic advantage: sermorelin-induced GH release occurs in pulses that align with the body's natural secretory rhythm—typically peaking 30–60 minutes post-administration and returning to baseline within 90–120 minutes. This pulsatile pattern preserves negative feedback regulation through somatostatin, which is released from the periventricular nucleus in response to elevated GH and IGF-1 levels. Somatostatin inhibits further GH secretion, preventing supraphysiological spikes. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that sermorelin administration in adults aged 45–65 increased peak GH secretion 4.2-fold without suppressing basal pituitary function or elevating IGF-1 beyond the upper physiological range.
- Recombinant HGH (somatropin), by contrast, is bioidentical to the 191-amino-acid polypeptide hormone produced by somatotroph cells—but it's manufactured through recombinant DNA technology in E. coli or mammalian cell lines. When injected subcutaneously, HGH enters circulation directly, bypassing the hypothalamic-pituitary axis. Serum GH levels rise within 3–6 hours and remain elevated for 12–18 hours depending on dose. Because the hormone is delivered exogenously, the pituitary does not participate in secretion—and prolonged administration can suppress endogenous GH production through negative feedback on both GHRH secretion and somatotroph responsiveness. This is why patients who discontinue long-term HGH therapy often experience a rebound suppression period where natural GH secretion is blunted.